Olamic Pharma

Olamic Pharma is a clinical-stage biotechnology company focused on developing next-generation small molecule therapeutics for inflammatory and autoimmune diseases. The company utilizes a proprietary "soft drug" design platform to create potent inhibitors that act locally at the site of disease before being rapidly inactivated in the systemic circulation, thereby minimizing systemic side effects. Its lead candidate, OLM-101, is a topical Janus kinase (JAK) inhibitor designed for the treatment of skin conditions such as atopic dermatitis. By leveraging this localized action, Olamic aims to provide the efficacy of systemic treatments with a significantly improved safety profile. The company's pipeline also includes programs targeting psoriasis and inflammatory bowel disease.